newswire, breaking biotechnology and pharma news

Monday, February 14, 2011

Biotech/ Pharma Stock Trading Alert; BioSante Pharmaceuticals Inc up on News

Point Roberts, WA. –February 14, 2011 ( Energy stocks Newswire) - and its leading Biotech investor portals, announces a technical stock
trading alert for BioSante Pharmaceuticals Inc (NASDAQ:BPAX). The stock is trading at $2.41,
up 0.10 (4.33%), trading as high as $2.53 in morning trading.

Recent News: BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Positive LibiGel Safety
Data in Phase III Program

“LINCOLNSHIRE, Ill. - February 14, 2011 BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX),
presented positive safety data in its ongoing LibiGel Phase III clinical development program, at
the annual meeting of ISSWSH on February 12, 2011.

BioSante reported that with 2,869 women enrolled and over 3,000 women-years of exposure
in its LibiGel Phase III cardiovascular and breast cancer safety study, there have been 17
adjudicated cardiovascular (CV) events, with a lower than anticipated event rate of approximately
0.57 percent. There have been eight breast cancers reported, a rate of approximately 0.27

Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-
agreed protocol, without modifications including continued enrollment of new subjects. This was
the recommendation of the independent Data Monitoring Committee (DMC) based on its 5th
unblinded review of all study safety data. LibiGel is in development for the treatment of female
sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal
women, for which there is no FDA-approved product.”
Full News at:

Recent News: BioSante Pharmaceuticals, Inc. To Present LibiGel®
Safety Study Update At BIO CEO & Investor Conference

“LINCOLNSHIRE, Illinois (February 14, 2011) – BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX) will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the
Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take
place February 14-15, 2011 at the Waldorf-Astoria in New York.

Stephen M. Simes, BioSante’s president & CEO, will speak today, Monday February 14, 2011
at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel®
(testosterone gel) Phase III clinical development program including safety data. A live audio
webcast of Mr. Simes’ remarks may be accessed at:

ceoinvestor2011/16113289.cfm .”
Full News at:

More info: About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female
sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal
testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III
clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol
Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have
been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other
products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to
Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante
patented technology. The company also is seeking opportunities for its other technologies.
Additional information is available online at:

Sign up for the free investor news letter and get stock alerts in leading

Research more biotech stocks at the Biotech stocks Directory: http://

About is a leading global investor and industry research resource portal specialized
in sector investing, covering leading industry sectors including mining and gold stocks, in addition
to global markets including China, India, the Middle East and Australia. is
known for its comprehensive stock directories in each sector and sector specific newswires.

About our Biotech investor portal: is a global meeting place for investors and industry following the
sector, within Global visitors use the site daily to research the latest news,
articles, audio, research reports and our stock directories.

Contact BioSante Pharmaceuticals

For Media:
Alan Zachary
(312) 506-5220;

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953; Disclosure, Disclaimer/ BPAX is a paid advertising client on (one thousand per month)

Disclaimer: The following news is paid for by BPAX (three thousand per month) is a third party publisher of news and research .Our sites do not make
recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. This site is currently compensated by featured companies, news
submissions and online advertising. Disclaimer: Disclosure:

Source:, BioSante,
Contact to become a biotech showcase stock or research biotech stocks
800 665 0411

No comments:

Post a Comment